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Abstract
Local delivery of chemotherapeutics in the cervicovaginal tract using nanoparticles may reduce
adverse side effects associated with systemic chemotherapy, while improving outcomes for early
stage cervical cancer. We hypothesize drug-loaded nanoparticles must rapidly penetrate
cervicovaginal mucus (CVM) lining the female reproductive tract to effectively deliver their
payload to underlying diseased tissues in a uniform and sustained manner. We develop paclitaxel-
loaded nanoparticles, composed entirely of polymers used in FDA-approved products, which
rapidly penetrate human CVM and provide sustained drug release with minimal burst effect. We
further employ a mouse model with aggressive cervical tumors established in the cervicovaginal
tract to compare paclitaxel-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles
(conventional particles , or CP) and similar particles coated with Pluronic® F127 (mucus-
penetrating particles , or MPP). CP are mucoadhesive and, thus, aggregated in mucus, while MPP
achieve more uniform distribution and close proximity to cervical tumors. Paclitaxel-MPP
suppress tumor growth more effectively and prolong median survival of mice compared to free
paclitaxel or paclitaxel-CP. Histopathological studies demonstrate minimal toxicity to the
cervicovaginal epithelia, suggesting paclitaxel-MPP may be safe for intravaginal use. These
results demonstrate for the first time the in vivo advantages of polymer-based MPP for treatment
of tumors localized to a mucosal surface.
Keywords
drug delivery; cancer; controlled release; chemotherapy; biodegradable polymers; Biomedical
Applications; Nanoparticles
1. Introduction
The vast majority of cervical cancer patients are diagnosed at early stages of the disease,
when tumors are confined to the cervix (Stage I) and remain small in size.[1] Nevertheless,
current standards of care for early stage cervical cancer generally fail to eradicate tumors
without significant adverse side effects: both surgery (excisional or ablative procedures) and
radiation therapy are associated with increased risks for future negative gynecological and
obstetric outcomes, such as impaired sexual function, infertility, preterm delivery and low
birth weight.[2] Systemic chemotherapy represents a third treatment option. However,
systemically administered drugs reach mucosal tissues, such as the epithelial surface of the
cervix, with very low efficiency. Thus, even high doses of chemotherapy typically fail to
elicit therapeutic responses, while causing significant systemic toxicity.[3] For these reasons,
systemic chemotherapy is generally the last option for cervical cancer treatment, and is often
used only concurrently with other treatments; it is rarely used for early stage disease.
Methods that enable sustained and localized chemotherapy delivery in the female
reproductive tract may reduce the adverse side effects commonly associated with systemic
chemo, while improving efficacy by providing higher drug concentrations at the tumor site
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over prolonged periods of time. However, the cervicovaginal (CV) epithelium is highly
permeable,[4] which not only limits the duration over which an adequate drug concentration
can be maintained locally, but also increases the likelihood of adverse systemic side effects,
particularly when higher dosages and/or repeated administration are needed. The high
permeability of the CV epithelium also likely contributes to the poor distribution of topically
administered free drugs, as previously demonstrated for various vaginal microbicides.[5]
Thus, vaginal instillation of unencapsulated chemo drugs is expected to provide minimal
therapeutic efficacy, and may cause significant systemic toxicity.
Nanoparticle-based drug and gene delivery systems have gained increasing interest for their
potential therapeutic or prophylactic applications in the female reproductive tract. A number
of nanoparticle-based platforms, including polymeric nanoparticles,[6] and quantum dots,[7]
have been developed that show potential in animal models for preventing sexually
transmitted infections,[8] prophylaxis against the development of cervicovaginal tumors,[9]
and improved siRNA delivery[10]. However, conventional polymeric nanoparticles,
including those composed of polymers used in FDA-approved products, poly(lactic-co-
glycolic acid) (PLGA) and polycaprolactone, are easily immobilized by the visocoelastic
and adhesive cervicovaginal mucus (CVM) secretions coating the CV epithelium.[6a–c, 11]
These conventional particles (CP) not only suffer from poor distribution in the CV tract, but
also are unlikely to access the deeper, more slowly cleared mucus layers near the epithelium
for prolonged retention and drug release.[8]
To address the limitations of mucosal drug delivery with standard polymer nanoparticles, we
developed “mucus-penetrating particles” (MPP) by coating nanoparticles with an
exceptionally dense layer of low MW poly(ethylene glycol) (PEG).[6a–c, 11–12] PEG is a
hydrophilic and uncharged polymer, which at sufficiently dense coverage can effectively
minimize adhesive interactions between nanoparticles and anionic glycans or periodic
hydrophobic naked protein domains on mucins.[12–13] Furthermore, we recently developed a
simple non-covalent coating process to produce MPP composed entirely of GRAS
(Generally Regarded As Safe by the FDA) materials.[6b] Here, we report the formulation of
an all GRAS, paclitaxel (PTX)-loaded drug carrier, composed of PLGA and Pluronic®
F127, that rapidly penetrates human CVM ex vivo and enhances the efficacy of PTX against
tumors in the reproductive tract of female mice.
2. Results and Discussion
2.1. Characterization of PTX-loaded nanoparticles and drug release in vitro
To develop a drug-loaded MPP system for potential treatment of cervical cancer, we
formulated nanoparticles composed of PLGA and Pluronic® F127 encapsulating PTX, a
frontline chemotherapeutic drug, by a nanoprecipitation method. Scanning electron
micrographs showed that both PLGA MPP encapsulating PTX (PTX/MPP) and the
corresponding conventional PLGA particles (formulated without F127; PTX/CP) possessed
smooth surfaces and a relatively uniform size distribution, with no visible drug precipitates
or impurities (Figure 1a,b). The narrow size distributions of PTX/MPP and PTX/CP were
confirmed by dynamic light scattering, with average diameters of 239 and 234 nm,
respectively (Table 1). The drug loading of PTX/MPP (~ 5% w/w) was comparable to that
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of PTX/CP (~ 8%) (Table 1). We also characterized the in vitro release of encapsulated PTX
from PTX/MPP and PTX/CP at pH 7.4 and 37°C; both particle types released PTX in a
similar fashion over 3 days with minimal burst release (Figure 1c). In general, PTX/MPP
and PTX/CP showed similar physical characteristics, and provided sustained release of PTX
at comparable rates.
2.2. PTX/MPP rapidly penetrate human CVM
To test whether PTX/MPP were capable of diffusing rapidly in mucus secretions, we
measured their transport rates in human CVM using multiple particle tracking.[11, 14] The
time-lapse traces of PTX/MPP in CVM resembled unobstructed Brownian motion (Figure
2a); in contrast, the trajectories of PTX/CP in the same CVM samples were highly
constrained and non-Brownian (Figure 2b). We quantified particle transport rates in the form
of an ensemble-averaged geometric mean squared displacement (<MSD>), and found that
the <MSD> of PTX/MPP was > 6,500-fold higher than that of PTX/CP at a time scale of 1s
(Figure 2c). Overall, PTX/CP were slowed on average > 40,000-fold in CVM compared to
their theoretical speeds in water, whereas PTX/MPP were slowed only 6-fold (Table 1). The
distributions of the logarithms of individual particle effective diffusivities showed the
greater ensemble average mobility of PTX/MPP was due to a near-uniform increase in
particle speeds for PTX/MPP compared to PTX/CP, and not due to a small fraction of fast
moving outlier nanoparticles (Figure 2d).
The average size of PTX/MPP and PTX/CP was 230–240 nm, smaller than the average
mesh size of the mucin network in human CVM (estimated average ~ 340 nm, with 80% of
pores larger than 200 nm in diameter[15]). Thus, steric exclusion of both types of particles by
the mucus gel should be minimal. The greatly improved mobility of PTX/MPP compared to
PTX/CP in human CVM may therefore be attributed largely to the formation of an effective
muco-inert shield by surface-coated F127. The surface charge and mobility of PTX/MPP
were comparable to those of similarly sized blank MPP reported previously,[6b] suggesting
the incorporation of PTX did not interfere with surface coating by F127.
2.3. Characterization of intravaginal cervical tumor model by bioluminescence and
magnetic resonance imaging (MRI)
A key challenge to demonstrating improved in vivo efficacy by MPP is the choice of an
animal model that features a mucus barrier to allow differentiation of the in vivo
performance of MPP vs. CP. Here, we employed a tumor model of cervical cancer
established by locally implanting TC-1 tumor cells in the mouse vagina,[16] which has a
CVM layer. TC-1 cells, genetically modified to express luciferase enzyme,[17] were applied
intravaginally, allowing the cells to attach to and proliferate in the CV epithelium. MRI has
been used previously to delineate cervical cancer based on its superb soft tissue contrast,[18]
and we employed T2-weighted anatomical MRI to confirm tumor implantation and to
evaluate the progress of tumor growth. TC-1 tumors grew along the length of the CV tract
and extended laterally toward surrounding tissues (Figure 3a–c). We also quantified tumor
growth via bioluminescence imaging on live animals and characterized physical tumor
weight at predetermined intervals. We found a near linear correlation between the
bioluminescence signal and tumor weight (Figure 3d), suggesting the bioluminescent TC-1
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tumor model affords accurate assessment of tumor size. This enables high-throughput
longitudinal monitoring of tumor growth in the same mice in a non-invasive fashion.
The TC-1 model offers a number of desirable features for the current study. TC-1 cells are
immortalized murine epithelial cells that were transformed to express HPV-16 E6/E7 and
activated human c-Ha-ras oncogene, i.e., they exhibit similar genetic traits as human
papillomavirus (HPV)-induced cervical tumors.[19] We previously showed that the TC-1
model also recapitulates many of the aspects of cervical cancer tumor progression in the
cervicovaginal tract.[16] These cells consistently produce highly aggressive tumors, and are
thus a stringent model for testing new therapeutic approaches within a short time frame.
Finally, the localization of tumors to the mouse CV tract not only resembles the anatomy of
the human disease, but also features a CVM layer that acts as a barrier to particle
penetration, making this model well-suited for testing whether muco-inert MPP may provide
more effective drug delivery in vivo than mucoadhesive CP.
2.4. MPP distribute more uniformly than CP in the mouse CV tract
We next sought to determine whether the ability of PTX/MPP to penetrate human CVM ex
vivo may lead to improved particle penetration across the protective mucus layer in the
mouse vagina, as compared to PTX/CP. We administered fluorescently labeled MPP or CP
suspension to the vaginas of mice bearing TC-1 tumors, and harvested the entire vagina
from each mouse after 20 hr. Fluorescent images of transverse cross-sections of vaginal
tissue show that CP aggregated and remained localized in the lumen of the vagina, failing to
penetrate the mucus barrier and reach tumors (Figure 4a). In contrast, MPP remained well-
dispersed and distributed uniformly, including in close proximity to the epithelial surface
and tumors (Figure 4b).
We previously demonstrated that enhanced mucus penetration can lead to improved
distribution of MPP over the mucosal surface of a healthy mouse vaginal tract.[8] Our results
here confirm that MPP also spread more uniformly than CP in mice bearing vaginal tumors.
The uniform distribution of MPP over the epithelial surface may allow the particles to
achieve a higher concentration of PTX in closer proximity to tumors, which may more
effectively suppress tumor growth. In contrast, CP aggregated in the vaginal lumen, likely
due to their strong mucoadhesive properties,[8] preventing them from reaching tumor tissues
and precluding sustained drug release in proximity to tumors. Aggregation of CP in mucus
may also reduce the amount of drug released over time due to a lower effective surface
area,[20] potentially further reducing the therapeutic efficacy of CP.
2.5. PTX/MPP provide sustained drug retention in the mouse CV tract
When delivered topically in the CV tract, Taxol®, the clinical formulation of PTX dissolved
in Cremophor®/ethanol, is readily eliminated due to systemic absorption across the highly
permeable vaginal epithelium. We therefore sought to determine whether PTX/MPP can
prolong drug retention in the mouse CV tract compared to Taxol® administered
intravaginally (local Taxol®) or intraperitoneally (systemic Taxol®), by quantifying PTX
extracted from the mouse CV tract over time (Figure 5). In the local Taxol® group, the
amount of drug in the CV tract decreased rapidly to ~ 14% of the initial dose by 4 hr, and
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only ~ 1% of the initial dose by 24 hr. In contrast, in the PTX/MPP group, the amount of
retained drug, in the form of both released drug and encapsulated drug in PTX/MPP,
decreased at a much slower rate, with ~ 70% of the initial dose remaining 24 hr post-
administration. In the systemic Taxol® group, drug levels were below the detection limit at
all time points, suggesting a limited amount of drug reached the CV tract through systemic
circulation. The prolonged retention of PTX by PTX/MPP may be attributed to the slow
elimination of MPP by mucus clearance,[8] as well as the sustained release of drugs from the
particles. Sustained retention of PTX provided by MPP may enhance tumor suppression by
maintaining a stable, therapeutically effective level of PTX at tumor sites, which is not
achievable by local or systemic Taxol®.
2.6. PTX/MPP effectively suppress tumor growth in the mouse CV tract
We next evaluated the therapeutic efficacy of PTX/MPP compared to PTX/CP and Taxol®
in our cervicovaginal tumor model. Beginning 3 days after tumor inoculation, mice were
treated daily with an intravaginal dose of PTX/MPP, PTX/CP or Taxol®, each at 3 mg/kg of
PTX. Tumors in the control group grew rapidly without treatment (Figure 6a). By Day 11,
the total tumor load, as reflected by bioluminescence measurements, was 115-fold higher
than that at Day 3. The tumor growth rate in the local Taxol® group was slightly slower,
with an overall tumor load equal to ~ 60% of the control group by Day 11. PTX/CP
exhibited slightly improved efficacy compared to local Taxol®, with an average
bioluminescence signal of ~ 42% that of the control group at Day 11. In contrast, the tumor
load for the PTX/MPP group was only ~ 7% that of the control group at Day 11, statistically
lower than that of any other group (p < 0.05). Based on Kaplan-Meier survival curves, local
Taxol® and PTX/CP only extended the median survival time to 11 days vs. 9 days for the
untreated control group, a difference that was not statistically significant (Figure 6b). In
comparison, PTX/MPP doubled the median survival time to 19 days, a result that was
statistically significant compared to all other treatment groups.
Since PTX/CP exhibited a similar size distribution and drug release profile as PTX/MPP, the
lower efficacy of PTX/CP against cervical tumors was likely due to their inability to
penetrate mucus. In contrast, PTX/MPP were able to penetrate the mucus layer lining the
vaginal epithelium, thereby achieving a more uniform distribution and maintaining an
elevated and sustained level of PTX in close proximity to tumors. These factors likely
contribute critically to improved suppression of tumor growth by MPP in the aggressive
TC-1 tumor model. MPP may also enhance suppression of other tumors localized to
mucosal surfaces, such as early-stage lung or colorectal tumors, where mucus serves as a
critical barrier to locally delivered therapeutics. In addition, the therapeutic advantages of
MPP may be even more pronounced in cancers with abnormally elevated mucus secretion,
for example, in adenocarcinomas.
It should be noted that the TC-1 tumor model is very aggressive, with tumor volume
reaching 2,000 mm3 in less than 30 days if left untreated.[16] In comparison, other cervical
cancer models, such as transgenic models requiring sophisticated genetic
modifications,[9, 21] models induced by vaginally administered carcinogen,[22] or models
involving surgically implanted tumor xenografts,[23] usually take much longer to establish.
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While the fast establishment of TC-1 tumors enables efficient evaluation of new
chemotherapeutic systems, the aggressiveness of tumor growth also makes complete
suppression unlikely. As tumor size increases over time, the ability of drugs to penetrate into
the tumor likely decreases. Elevated interstitial pressure within tumor tissue significantly
reduces convection-driven transport of drug molecules into tumors.[24] In addition, binding
to tissue elements, drug metabolism and systemic absorption further reduce effective
diffusion of drug within tumor tissue.[25] Although the drugs may kill superficial layers of
tumor cells, their inability to penetrate into the tumor core may prevent complete eradication
of the tumor.[25] Thus, long-term survival of mice using the TC-1 model is very difficult to
achieve. Nevertheless, it is likely that PTX/MPP may more effectively suppress, or perhaps
even eradicate, early stage tumors in humans, which are typically much less aggressive than
TC-1 and progress much more slowly.[26] Future studies using alternative murine cervical
tumor models that are less aggressive and better resemble the slow tumor progression in
humans[9, 21–23] may further substantiate the effectiveness of PTX/MPP.
2.7. PTX/MPP are well tolerated in the mouse CV tract
Finally, vaginal histology was assessed for mice receiving the various treatment options at
24 and 48 hr after treatment (Figure 7). Overall, minimal toxicity was observed in all
groups, with no evidence of abnormal epithelial exfoliation or erosion and, at most, mild
inflammatory cell infiltrates. Compared to systemic Taxol®, all local treatment groups
(PTX/MPP, PTX/CP and local Taxol®) showed slightly greater cytotoxicity, consistent with
the higher local concentration of PTX. At 24 hr after treatment, changes in nuclear
morphology (chromatin clumping, nuclear fragmentation) were evident in a minority of
vaginal epithelial cells, and particularly basal cells, for all local treatment conditions.
Similarly, a slight increase in the number of apoptotic epithelial cells was noted after 48 hr
in all three groups treated intravaginally compared to mice treated with systemic Taxol®.
Both PTX/MPP and PTX/CP groups showed minimal to mild inflammatory cell infiltrate at
24 hr, which resolved by 48 hr. Systemic Taxol® and local Taxol® groups showed no
increase in inflammation above background level. Histology of all intravaginally treated
groups was normal at 6 days after treatment. These results indicate vaginal PTX/MPP
treatment was well-tolerated with no severe adverse effects in the mouse CV tract.
In contrast to polymeric particles composed of PEG-containing block copolymers or pre-
fabricated particles with covalently attached PEG coatings, Pluronic-coated particles, such
as the PLGA/F127 MPP system described here, do not generate any covalent linkages that
would constitute a new chemical entity to the FDA. Thus, the safety profile of the particles
is likely equivalent to those of its components, PLGA and Pluronic, both of which are well
known for their biocompatibility and use in a broad range of FDA-approved pharmaceutical
products.[6b, 27] We expect that the all-GRAS nature of the PLGA/F127 system will
facilitate faster, more economical, and more scalable translation to human clinical trials.
3. Conclusions
In this study, we developed a drug-encapsulated polymer-based MPP platform entirely
composed of materials used in FDA-approved products, and showed that MPP released drug
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continuously over 3 days in vitro. MPP remained well-dispersed and distributed uniformly
across the vaginal mucosal surface, achieving close proximity to tumors established in the
mouse CV tract. Local PTX/MPP suppressed the growth of aggressive cervical tumors and
prolonged the median survival of mice more effectively than local PTX/CP or free Taxol®.
To our knowledge, this is the first demonstration that polymer-based MPP can provide
enhanced efficacy in an in vivo disease model. We expect that the biodegradable MPP
platform can be adapted to deliver a variety of therapeutics and, compared to conventional
mucoadhesive particles, achieve improved distribution and efficacy at other mucosal
surfaces, making them promising candidates for treating cancers localized to the mucosae.
4. Experimental
Nanoparticle preparation and characterization
PTX/MPP were prepared using a nanoprecipitation method similar to that previously
described.[6b, 28] Briefly, PLGA (15 kDa, L:G ratio ~ 50%:50%; SurModics
Pharmaceuticals, Inc., Birmingham, AL) and PTX (LC Laboratories, Woburn, MA) were
co-dissolved in acetonitrile (20 and 4mg/mL), respectively, and the polymer and drug
solution (1 mL) was added dropwise into Pluronic® F127 (BASF, Florham Park, NJ)
solution (40 mL, 10% w/v). PTX/CP were similarly prepared, and poly(vinyl alcohol)
(PVA, 25 kDa; Polysciences, Inc., Warrington, PA) was used in place of F127 to facilitate
PTX encapsulation. After stirring for 2 hr to remove the organic solvent, the nanoparticles
were collected by centrifugation at 11,648 ×g (Sorvall Legend X1R centrifuge; Thermo
Fisher Scientific Inc., Asheville, NC) for 20 min, washed twice, and used within 2 hr. To
characterize particle transport in human CVM, doxorubicin (NetQem, Durham, NC),
intrinsically fluorescent with excitation/emission maxima at 480/550 nm, was chemically
conjugated to PLGA as previously described.[29] Fluorescent PTX-loaded nanoparticles
were prepared following similar procedures to those described above using doxorubicin-
labeled PLGA. Particles formulated to assess in vivo distribution were prepared similarly but
without PTX or additional stabilizers besides F127. Doxorubicin-labeled PLGA was only
used to formulate particles for studies requiring observation of particles by fluorescence
microscopy (particle tracking and in vivo distribution, but not in vivo particle retention and
efficacy against cervical tumors). Size and ζ-potential of nanoparticles were determined by
dynamic light scattering and laser Doppler electrophoresis, respectively, using a Zetasizer
NanoZS90 (Malvern Instruments, Southborough, MA) following manufacturer instructions.
Particle morphology was characterized by scanning electron microscopy (SEM) using a cold
cathode field emission SEM (JEOL JSM-6700F, Peabody, MA). Nanoparticles were
lyophilized, resuspended in ethanol (100%) and dried onto SEM mounts at room
temperature. Particles were then sputter coated with platinum prior to imaging.
Characterization of drug loading and in vitro drug release profile
PTX/MPP and CP were lyophilized and subsequently dissolved in acetonitrile to extract
PTX. After centrifugation (15,000 ×g, 5 min) and filtration through a 0.2 µm PTFE filter, the
filtrate (50 µL) was injected into a Shimadzu High Performance Liquid Chromatography
(HPLC) system equipped with a C18 reverse phase column (5 µm, 4.6×250 mm; Varian
Inc., Santa Clara, CA). PTX was eluted using an isocratic mobile phase containing water
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and acetonitrile (35%:65%, v/v) at 1 mL/min and detected at 229 nm using a UV detector.
The data was analyzed using LCsolution software (Shimadzu Scientific Instruments,
Columbia, MD). Drug loading was defined as the weight ratio of drug to polymer. To
determine the drug release kinetics of the nanoparticles, 10 mg of PTX/MPP or CP was
suspended in PBS (40 mL, pH = 7.4), and octanol (5 mL) was added on top of the PBS, as
described previously.[30] At pre-determined time intervals, the octanol phase was collected
and replaced with fresh octanol. Quantitative analysis of released drug was performed using
HPLC after a 1:2 (v/v) dilution of the octanol release samples with acetonitrile. The data
was analyzed using LCsolution software.
High resolution multiple particle tracking
Human CVM was collected as previously described,[11] following a protocol approved by
the Johns Hopkins School of Medicine Institutional Review Board. Collected mucus
samples were stored at 4 °C until used for microscopy within 4 hr. Suspensions of
fluorescently labeled nanoparticles (~ 1010 particles/mL) were added at 3% v/v to human
CVM (20 µL) and samples were incubated 1 hr at 37 °C before microscopy. Particle
transport rates were measured by analyzing trajectories of fluorescent particles, recorded
using a silicon-intensified target camera (VE-1000; Dage-MTI, Michigan, IN) mounted on
an inverted epifluorescence microscope equipped with a 100× oil-immersion objective
(numerical aperture 1.3). Movies were captured using MetaMorph software (Molecular
Devices, Inc., Sunnyvale, CA) at a temporal resolution of 66.7 ms for 20 s. The tracking
resolution was 10 nm, as determined by tracking the displacements of particles immobilized
with a strong adhesive.[11] Trajectories of n > 100 particles were analyzed for each
experiment, and three experiments in CVM from different donors were performed for each
condition. The coordinates of nanoparticle centroids were transformed into time-averaged
mean squared displacements (MSD), <Δr2(τ)> = [x(t + τ) – x(t)]2 + [y(t+ τ) – y(t)]2 (τ = time
scale or time lag), from which distributions of MSDs and effective diffusivities were
calculated.[11, 14] The theoretical diffusivities of nanoparticles in water were calculated from
the Stokes-Einstein equation, Dw = kBT/6πηR, where the Boltzmann constant kB =
1.38×10−23 m2·kg·s−2·K−1, T = 293.15 K, the viscosity of water η = 0.001 Pa·s, and R as the
diameter of the nanoparticles.
Cervicovaginal tumor model and treatment
All experiments conducted with mice were performed in accordance with protocols
approved by the Johns Hopkins University Animal Care and Use Committee satisfying the
requirements of the E.E.C. Guidelines (1986) and U.S. Federal Guidelines (1985). C57BL/6
mice (6–8 weeks old) were treated with Depo-Provera® (medroxyprogesterone acetate, 2.5
mg/mouse) by subcutaneous injection into the right flank ~ 7 days prior to use. For tumor
inoculation, mice were anesthetized, and their cervicovaginal epithelia gently disrupted
using cytobrushes, before TC-1 tumors cells expressing luciferase were inoculated by
vaginal instillation (1×105 cells per mouse). [16] Tumor growth was monitored by live
animal bioluminescence imaging, and anatomical MRI was also performed ~ 7 days after
tumor inoculation to assess tumor growth. Detailed information on MRI analysis is
described in a different section. Beginning 3 days after tumor challenge, mice were treated
daily with an intravaginal dose (3 mg/kg) of PTX/MPP, PTX/CP or free drug (n = 5–6 mice
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per condition, mice were grouped to have similar starting levels of bioluminescence signals).
Mice were prevented from self-grooming following each treatment for ~ 12 hours by a
collar.[8] Mice with no treatment served as a negative control. Tumor growth was monitored
by live animal bioluminescence imaging at different time points. Bioluminescence signals
were analyzed using Living Image software (Caliper Life Sciences, Inc., Hopkinton, MA).
In brief, a circular region of interest (ROI) that includes the entire vaginal region was
created for each mouse, and its bioluminescence signal was measured as total photon flux
(p/s, photons per second). The same ROI size was used among all mice to ensure
consistency. For Kaplan-Meier survival curves, mice were excluded once the
bioluminescence signal reached 5×107 p/s as an indication of disease advancement.
Characterization of intravaginal cervical tumor model by MRI
To assess tumor growth, T2-weighted MR images were acquired ~ 7 days after tumor
inoculation using a 9.4T horizontal bore small animal scanner (Bruker BioSpin Corp.,
Billerica, MA) equipped with a 25 mm sawtooth resonator. In brief, a modified Rapid
Acquisition with a modified Relaxation Enhancement (RARE) sequence including a fat
suppression pulse (3.4 ms hermite pulse, offset = −3.5 ppm) was used to acquire the MR
images. The acquisition parameters were: TR = 3.0 s, effective TE = 18 ms, RARE factor =
8, slice thickness = 0.7 mm, acquisition matrix size = 256×128, in plane resolution = 167 µm
× 142 µm, and single acquisition (NA = 1). Multi-slice MR images were acquired along
three dimensions (coronal, sagittal and axial) of the CV tract.
Distribution of nanoparticles in the mouse vagina
To evaluate nanoparticle distribution in vivo, 5 µL of fluorescently labeled PLGA CP or
MPP suspension were administered intravaginally to mice bearing CT-1 tumors. After 20 hr,
the entire vagina was gently removed and frozen in Tissue-Tek® O.C.T.™ Compound
(Sakura Finetek U.S.A., Inc., Torrance, CA). Transverse sections were obtained at various
points along the length of the tissue (between the introitus and the cervix) using a Leica
Cryostat (Leica Microsystems Inc., Bannockburn, IL). The thickness of the sections was set
to 50 µm to minimize possible artifacts due to displacement of mucus and particles.
Fluorescent images of the sections were obtained using a LSM 510 confocal laser scanning
microscope (Carl Zeiss Inc., Thornwood, NY). Images in Figure 4 are representative of the
observations from 3 mice per particle type.
Retention of PTX in the mouse vagina
To evaluate the retention of PTX delivered in PTX/MPP or as free drug in the mouse vagina
quantitatively, we administered PTX/MPP and free Taxol® (clinical formulation of PTX)
intravaginally, with free Taxol® administered intraperitoneally as a systemic treatment for
comparison to local treatments. Mice were prevented from self-grooming through the entire
course of the study (24 hours) by an Elizabethan collar. At select time points up to ~ 24 hr,
mice were given 10× vaginal lavage with 30 µL of normal saline. The entire vagina was then
collected and treated with cell lysis buffer. The lavage and vaginal tissue samples were
lyophilized and acetonitrile was used to dissolve PTX in the lyophilized samples. The
amount of drug in each sample was quantified by HPLC.
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Assessment of intravaginal toxicity
To assess the toxicity caused by different treatments, PTX was administered intravaginally
or systemically at a dose of 3 mg/kg as free drug or encapsulated in PLGA nanoparticles (n
= 5 mice per treatment group). At the indicated times after dosing, mice were sacrificed and
the CV tissues collected. After fixation in neutral buffered formalin solution (10%), the
tissue samples were routinely processed and embedded in paraffin wax. For histological
analysis, 5 µm thick sections were taken at 100 µm intervals, and stained with hematoxylin
and eosin. Two sections from each mouse were reviewed in a blinded fashion by a
pathologist and scored in a semi-quantitative fashion according to established guidelines for
evaluating vaginal toxicity/irritation [31], modified to include assessment for toxic effects of
Taxol®. Sections were evaluated for multiple injury parameters including leukocyte
infiltration, epithelial exfoliation, vascular congestion and edema. Polymorphonuclear
leukocyte infiltration was identified by the characteristic multi-lobed nuclei of these
inflammatory cells. Pyknotic and apoptotic cells were identified by condensed,
hyperchromatic or fragmented nuclei and shrunken, eosinophilic cytoplasm.
Statistical analysis
All data are presented as a mean with standard error of the mean (S.E.M.) indicated.
Statistical significance of in vivo drug retention values (Figure 5) was performed using one
way analysis of variance (ANOVA) followed by Tukey’s test. Differences in tumor burden
(Figure 6a) and survival (Figure 6b) between treatment groups were evaluated using a
Kruskal-Wallis ANOVA and a Log-rank (Mantel-Cox) test, respectively. All other statistical
analyses were performed using one-tailed Student’s t-tests, assuming unequal variance. P-
values < 0.05 were considered statistically significant.
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Characterization of PTX/PLGA nanoparticles in vitro. Scanning electron micrographs of
PTX/MPP (a) and PTX/CP (b); scale bar represents 1 µm. (c) Cumulative in vitro release of
PTX from PTX/PLGA nanoparticles over time. Data represent the average values from two
independent studies using different particle preparations. Error bars represent S.E.M.
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Transport of PTX-loaded PLGA particles in fresh human cervicovaginal mucus.
Representative trajectories for (a) PTX/MPP and (b) PTX/CP, with effective diffusivities
within one S.E.M. of the mean. (c) Ensemble-averaged geometric mean square
displacements (<MSD>) as a function of time scale. Error bars represent S.E.M. * indicates
statistically significant difference across all time scales (p < 0.05). (d) Distributions of the
logarithms of individual particle effective diffusivities (Deff) at a time scale of 1 s. Data
represent the average of at least three independent experiments, with n ≥ 100 per experiment
for both PTX/MPP and PTX/CP.
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Magnetic resonance imaging (MRI) and bioluminescence imaging of TC-1 cervical tumors
implanted in the mouse cervicovaginal tract. Representative coronal (a), sagittal (b), and
axial (c) anatomical MR images of the female mouse reproductive tract, with yellow arrows
indicating the location of the TC-1 tumor and the green arrow indicating the location of CV
tract. The size of the tumor shown was measured to be 4.3 mm × 1.5 mm × 4.7 mm in the
coronal, sagittal and axial directions, respectively. (d) Correlation of total bioluminescence
and TC-1 tumor weight. Bioluminescence signals were quantified as the total photon flux
(p/s, photons per second) of the tumor regions. The top row of images shows the tumor
location and relative biolumniscence intensity, and the bottom row shows the physical
appearance of the excised tumors. Error bars represent S.E.M. Scale bars represent 5 mm.
Yang et al. Page 18























Transverse 50 µm thick frozen sections of mouse vaginal tissue containing red fluorescent
(a) PLGA CP or (b) PLGA MPP. Green corresponds to TC-1 cervical tumor expressing
GFP. The epithelium is outlined in white to help distinguish the tissue surface. Arrows
indicate the presence of large particle aggregates in the CV tract with PLGA CP in (a), while
arrowheads indicate examples of well-dispersed PLGA MPP in (b). The same image
acquisition and contrast settings were used for both images.
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Amount of PTX retained in the mouse CV tract over time, as delivered by PTX/MPP or as
free drug by vaginal administration (local Taxol®) or by intraperitoneal administration
(systemic Taxol®). The fraction of drug retained in the vagina is expressed as a percentage
of the total amount of drug administered. * indicates statistically significant difference
compared to free drug at the same time point (p < 0.05). Data represent at least n = 3 mice
per condition and time point. Error bars represent S.E.M.
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Response of TC-1 tumors established in the mouse cervicovaginal tract to local treatments
with untreated control, free Taxol®, PTX/CP or PTX/MPP (n = 5–6 mice per treatment
group). Tumors were inoculated on Day 0; treatments were given daily starting on Day 3.
(a) Change in bioluminescence signal over the indicated time course. Signals were
quantified as the total photon flux (p/s, photons per second) of the tumor regions. Error bars
represent S.E.M. * indicates significantly improved tumor suppression (p < 0.05) compared
to other treatments starting from Day 7. (b) Kaplan-Meier survival curves for mice bearing
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cervicovaginal TC-1 tumors. * indicates significantly improved survival rate (p < 0.05)
compared to other treatments starting from Day 13.
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Histological sections of cervicovaginal tissue from mice treated with systemic Taxol®, local
Taxol®, PTX/CP or PTX/MPP at 24 hr and 48 hr post administration (n = 5 mice per
treatment group). Note the presence of pyknotic and apoptotic cells (arrows, right side inset)
in local treatment groups at 24 hr and 48 hr, and inflammatory cells (arrowheads, left side
inset) in PTX/CP and PTX/MPP treated mice at 24 hr.
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Table 1
Characterization of PTX/ MPP and PTX/CP, and ratios of the ensemble average diffusion coefficients in water








PTX/ MPP 239 ± 5 −7 ± 1 5.2 ± 0.9 6
PTX/ CP 234 ± 4 −1 ± 1 8.7 ± 2.2 41,000
a)
Effective diffusivity values are calculated at a time scale of 1s. Dw is calculated from the Stokes-Einstein equation.
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